1. Scrip
  2. >>Focus On Asia
  3. >>China

Zai Lab Joins Latest Oncology Race With Mirati KRAS Deal

 
• By Dexter Jie Yan

Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.

competition
ZAI LAB JOINS KRAS RACE IN CHINA WITH MIRATI DEAL • Source: Alamy

Chinese biotech companies are in hot pursuit of best-in-class oncology therapies, as shown by Zai Lab Ltd. in-licensing exclusive commercial rights to a KRAS G12C mutation drug in Greater China from Mirati Therapeutics, Inc.

The deal was announced hot on the heels of the US Food and Drug Administration approval of Amgen, Inc.’s Lumakras (sotorasib) on 28 May. KRAS was considered to be an undrugable mutation until recently, despite being in the cross-hairs of global developers over the past more than 40 years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.